| Market Cap | $325.67M+4.2% |
| Revenue (ttm) | $32.28M |
| Net Income | -$91.09M |
| EPS | -$0.63 |
| Shares Out | 131.32M |
| PE Ratio | n/a |
| Forward PE | -3.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,628,833 |
| Open | $2.39 |
| Previous Close | $2.44 |
| Day's Range | $2.32 - $2.54 |
| 52-Week Range | $1.69 - $5.17 |
| Beta | 3.16 |
| Analysts | Strong Buy |
| Price Target | $12.50(+404.03%) |
| Earnings Date | Nov 5, 2026 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating CCCC in the last 3 months, one vote each. Issuer-paid research is not counted.
$CCCC stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CCCC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CCCC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CCCC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CCCC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CCCC from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from CCCC’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.44% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.22% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.17% |
| IWC | iShares Micro-Cap ETF | 0.07% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.07% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.04% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| IBB | iShares Biotechnology ETF | 0.02% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
Weight is the stock’s share of each fund’s holdings.
